ImmunoGen, Inc. IMGN is a clinical-stage biotechnology company, which focuses on developing targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology. This Waltham, MA-based company has several candidates in its pipeline.The company’s pipeline includes – mirvetuximab soravtansine for ovarian cancer and certain other FRa-positive solid tumors, IMGN529 and coltuximab ravtansine, for diffuse large B-cell lymphoma and other B-cell malignancies.The company earns revenues from royalties, license and milestone payments, and research and development support fees paid by its partners.ImmunoGen’s track record has been disappointing. The company reported wider-than-expected losses in three of the last four quarters, and met estimates on one occasion, with an average negative surprise of 8.35%.With ImmunoGen not having any approved products in its portfolio, investor focus should remain on pipeline updates since a number of pipeline related activities are lined up for the coming quarters.Currently, ImmunoGen has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:Earnings: ImmunoGen posted wider-than-expected quarterly loss. Our consensus called for a loss of 30 cents per share, and the company reported a loss of 37 cents per share.Revenues: Revenues also missed expectations. ImmunoGen posted revenues of $19.7 million, compared to our consensus estimate of $25 million.Key Stats: ImmunoGen continues to progress with its pipeline. The company is currently enrolling patients in a phase Ib/II study (FORWARD II) on its lead candidate, mirvetuximab soravtansine, combination with other approved anticancer agents, for the treatment of ovarian cancer. In addition, ImmunoGen has initiated a phase I study on IMGN779 for the treatment of acute myeloid leukemia.ImmunoGen has updated its guidance for its fiscal 2016. Revenues are now expected in the range of $60–$70 million, compared to the previous guidance of $70–$80 million.Check back later for our full write up on earnings report later!Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IMMUNOGEN INC (IMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research